MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics 
Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17, 2023 at 1:00 PM ET PHILADELPHIA, PA and LA JOLLA, CA, Jan. 11,...
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the...
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA...
Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing
COLUMBUS, Ohio, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term...
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™
BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
Research collaboration to target severe form of genetic dilated cardiomyopathyCollaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac...
Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference
Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing...
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...
Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives
SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic...
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic...
iCAD Announces Board of Directors Transition
Dana Brown named Executive Chair of the BoardNASHUA, N.H., Jan. 11, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical...
Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity
Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023BOULDER, Colo., Jan. 11, 2023...
ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue
SOLANA BEACH, Calif., Jan. 11, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform...
Genetic Technologies Provides Business Update
MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based...
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company CELEBRATION, Fla., Jan. 11, 2023...
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market...
Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022
Fourth Quarter Net Revenue of $2.6 Million; Full-Year Net Revenue of $10.0 Million;Active Customer Sites Continue to Climb SOUTH ORANGE,...
Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab
Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial SolutionsMORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health®...
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...